Back to Search
Start Over
YKL-40 in patients with end-stage renal disease receiving haemodialysis
- Source :
- Biomarkers; May 2018, Vol. 23 Issue: 4 p357-363, 7p
- Publication Year :
- 2018
-
Abstract
- AbstractPurpose:This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40.Methods:Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment.Results:A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL−1(IQR: 193–291 µgL−1) before HD treatment and 198 µgL−1(IQR: 147–258 µgL−1) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9%. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95% CI: 2.2–7.3, p < 0.001) for all-cause mortality which decreased to 2.4 (95% CI: 1.1–4.5, p = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment.Conclusion:YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.
Details
- Language :
- English
- ISSN :
- 1354750x and 13665804
- Volume :
- 23
- Issue :
- 4
- Database :
- Supplemental Index
- Journal :
- Biomarkers
- Publication Type :
- Periodical
- Accession number :
- ejs45494138
- Full Text :
- https://doi.org/10.1080/1354750X.2018.1428359